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Background
Skeletal  muscle  insulin  resistance  is  an  early  feature 
during  the  progression  towards  type  2  diabetes  (T2D) 
and  is,  in  its  own  right,  considered  a  risk  factor  for 
cardiovascular  disease.  While  the  defects  in  insulin-
mediated glucose flux have been widely described, the 
global  molecular  characteristics  of  insulin  resistant 
skeletal muscle have not. Four small gene-chip studies, 
relying on partial coverage of the human transcriptome, 
have attempted to define the global molecular basis of 
insulin resistance in human skeletal muscle [1-4]. While 
pioneering, neither the Yang et al. [4] nor Sreekumar et 
al. [3] studies were genome-wide, both studies suffered 
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high false-positive rates. In the third and fourth studies, 
by Mootha et al. [1] and Patti et al. [2], a coordinated 
down-regulation  of  oxidative  phosphorylation  related 
(OXPHOS) genes in the skeletal muscle of patients was 
the only change reported and this was proposed to be the 
underlying  cause  of  skeletal  muscle  insulin  resistance 
[5-7]. Indeed, ‘subset’ analysis of a collection of genes (for 
example, 200 to 400) has become a powerful approach to 
detecting coordinated defects in biological pathways in 
vivo, and this method has made important contributions 
to the systems biology field. A separate line of investi-
gation  by  Petersen  et  al.  [8,9]  introduced  a  magnetic 
resonance  spectroscopy  approach  [10]  to  study  insulin 
resistance in vivo [11]. This method estimates unidirec-
tional  ATP  synthesis,  but  it  is  unclear  if  it  has  been 
validated to take into account the multiple assumptions 
that allow net ATP generation to be calculated [12,13]. 
Despite the clear caveats and continuing debate in the 
field  [14,15],  the  concept  of  an  OXPHOS  impairment 
[5,16,17] is widely accepted. Nevertheless, a clear expla-
na  tion for the general lack of mRNA abundance changes, 
beyond OXPHOS mRNAs, still remains to be explained. 
One thing that it is certainly not due to is the lack of 
sensitivity of gene-chip technology as it readily detects 
high and low abundance RNA molecules under a variety of 
conditions [18-20]. In addition, the general lack of a global 
transcriptional signature has been a consistent finding.
Non-coding RNA has emerged in recent years [21] as 
being  of  functional  importance  [22].  In  particular, 
microRNAs (miRNAs) are accepted regulators of mamma-
lian  cell  phenotype  [23-25].  miRNAs  are  approximately 
22-nucleotide  post-transcriptional  regulators  of  gene 
product  abundance,  able  to  block  the  translation  of 
protein-coding genes [26]. miRNAs regulate development 
and differentiation [27,28] and brain and skeletal muscle 
tissue  have  the  most  abundant  expression  of  tissue-
specific miRNA species [29]. miRNAs have been impli-
cated in the regulation of metabolism [27,30] and insulin 
secretion  [31]  while  expression  is  altered  in  extreme 
muscle disorders [20,32]. Whether miRNAs are altered 
during  the  development  of  diabetes  or  skeletal  muscle 
insulin resistance in humans is unknown, and there are 
still very few studies characterizing miRNA changes in 
vivo,  in  humans.  The  molecular  rules  governing  the 
target  ing of each miRNA to individual genes have been 
documented  [25,33]  and  help  identify  which  protein 
coding genes are targeted when a single miRNA is modu-
lated in a cell [23,24]. In contrast, multiple changes in 
miRNA abundance can occur in vivo [32], where simul-
taneously up-regulated and down-regulated miRNAs can 
target  the  same  gene  but  with  a  range  of  predicted 
efficacies [25]. To date no study has established the net 
biological impact of multiple miRNA changes in vivo.
In  the  present  study  we  devised  a  new  strategy  for 
predicting which proteins and biological pathways would 
be altered in vivo under such circumstances (Figure S1 in 
Additional file 1). Our approach was built on the in vitro 
molecular rules encompassed by the site-specific context 
score criteria, as these criteria can significantly enrich a 
gene  list  in  genuine  targets  when  a  single  miRNA  is 
studied in a cell-based system [34]. Using three to nine 
times the number of human subjects (n = 118) as pre-
vious studies [1-4] and a more comprehensive ‘genome-
wide’ RNA profiling strategy (>47,000 mRNA sequences, 
and >500 miRNA sequences), we aimed to identify the 
global  molecular  nature  of  skeletal  muscle  insulin 
resistance in human T2D and provide new bioinformatic 
and protein level validation for our conclusions.
Methods
We recruited 118 subjects for the study (Table 1) and the 
degree of insulin resistance was verified by applying the 
World  Health  Organization  diagnostic  criteria  for  dia-
betes [35]. Exclusion criteria were treatment with insulin, 
recent or ongoing infection, history of malignant disease 
or treatment with anti-inflammatory drugs. The cohort 
consisted  of  approximately  65%  male  and  35%  female 
subjects. Participants were given both oral and written 
information  about  the  experimental  procedures  before 
giving  their  written,  informed  consent.  The  study  was 
approved by the Ethical Committee of Copenhagen and 
Frederiksberg Communities, Denmark (j.nr (KF) 01-141/04), 
and performed according to the Declaration of Helsinki.
Clinical evaluation protocol
Participants  reported  between  8  and  10  am  to  the 
laboratory after an overnight fast. Subjects did not take 
their usual medication for 24 hours preceding the exami-
nation,  and  T2D  subjects  did  not  take  hypo  glycemic 
Table 1. Characteristics of the 3 subject populations in the 
study
  T2D (n = 45)  IGT (n = 26)  NGT (n = 47)
Age  54.8 ± 10.2  56.4 ± 10.7  51.3 ± 10.7
BMI  31.4 ± 6.2  30.9 ± 6.1  31.1 ± 7.2
VO2max  26.9 ± 8.4  28.2 ± 9.7  29.5 ± 10.5
Fasting glucose  9.8 ± 4.4*  5.9 ± 0.5†  5.0 ± 0.4
Fasting insulin  91.2± 8.9†  88.2± 13.5‡  56.6± 8.3
HOMA1log  0.67± 0.07*  0.46± 0.05*  0.20± 0.05
2-h glucose (OGTT)  17.9 ± 5.5*  7.4 ± 2.4†  5.5 ± 1.2
HbA1c  7.4 ± 1.8*  5.8 ± 0.3†  5.5 ± 0.2
Data are mean ± standard deviation. BMI, body mass index; 
VO2max, ml/kg/minute; Fasting glucose and 2-h glucose tolerance is mmol/L; 
HbA1c is percentage glycosylated hemoglobin. *P < 0.001 when compared with 
either NGT or IGT; †P < 0.01 when compared with the NGT group; ‡P = 0.07 when 
compared with the NGT group. OGTT, oral glucose tolerance test.
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correlation between fasting glucose and hbA1c remained 
high (R2 = 0.71; Additional file 2), indicating that short-
term  glucose  homeostasis  did  not  appear  greatly 
disrupted by the 1-week drug withdrawal. Body mass and 
height  were  determined  for  body  mass  index  (BMI) 
calculations.  The  subjects  performed  an  oral  glucose 
tolerance test and an aerobic capacity test. Peak aerobic 
capacity was determined by the Åstrand-Ryhming indirect 
test of maximal oxygen uptake (VO2max) [36].
Blood analyses and oral glucose tolerance test
Blood samples were drawn before and 1 and 2 hours after 
drinking  500  ml  of  water  containing  75  g  of  dissolved 
glucose.  The  World  Health  Organization  diagnostic 
criteria  were  applied,  as  were  calculations  of  insulin 
resistance  (homeostatic  model  assessment  (HOMA)). 
Plasma was obtained by drawing blood samples into glass 
tubes  containing  EDTA  and  serum  was  obtained  by 
drawing blood into glass tubes containing a clot-inducing 
plug.  The  tubes  were  immediately  spun  at  3,500  g  for 
15 minutes at 4°C and the supernatant was isolated and 
stored  at  -20°C  until  analyses  were  performed.  Plasma 
glucose  was  determined  using  an  automatic  analyzer 
(Cobas Fara, Roche, France). All samples and standards 
were run as duplicates and the mean of the duplicates 
was used in the statistical analyses.
Muscle tissue biopsies
Muscle biopsies were obtained from the vastus lateralis 
using the percutaneous needle method with suction [37]. 
Prior to each biopsy, local anesthetic (lidocaine, 20 mg ml-1; 
SAD,  Denmark)  was  applied  to  the skin  and  superficial 
fascia of the biopsy site. Visible blood contamination was 
carefully  removed  and  all  biopsies were  frozen  in  liquid 
nitrogen  and  subsequently  stored  at  -80°C until  further 
analysis. RNA  extraction  was  carried  out  using  TRIzol 
(Invitrogen,  Carlsbad,  CA,  USA)  and  a  motor-driven 
homogenizer (Polytron, Kinematica, Newark, NJ, USA) as 
described [38].
Affymetrix microarray
Hybridization,  washing,  staining  and  scanning  of  the 
arrays  were  performed  according  to  manufacturer’s 
instruc  tions  (Affymetrix,  Inc.  [39]).  We  utilized  the 
Affymetrix U133+2 array platform and 15 µg of cRNA 
was loaded onto each chip. All array data were normal-
ized using the Microarray Suite version 5.0 (MAS 5.0) 
algorithm to a global scaling intensity of 100. Arrays were 
examined using hierarchical clustering to identify outliers 
prior to statistical analysis, in addition to the standard 
quality assessments, including scaling factors and NUSE 
plot.  No  array  included  in  this  analysis  failed  these 
standard  quality  assurance  procedures.  We  relied  on 
several statistical approaches to analyze the data with and 
without pre-filtering of gene lists. We utilized custom chip 
definition  files  (CDFs)  [40]  to  improve  the  anno  ta  tion 
precision  [41].  Using  the  MAS  5.0-generated  present-
absent calls improves the sensitivity of the differential gene 
expression analysis [42] as it increases the statistical power 
of the analysis. We chose to remove probe sets that were 
declared ‘absent’ across all chips in the study. The micro-
array data were subjected to global normalization using 
the robust multi-array average expression measure (RMA) 
in the Bioconductor suite [43] and analyses were compared 
in parallel with MAS 5.0-based normalization, following 
the negative result (see below) with the MAS 5.0 data. The 
CEL  files  have  been  deposited  at  the  Gene  Expression 
Omnibus under reference number [GEO:GSE18732] and 
patient pheno  type data have also been made available at 
the same location and with this manuscript.
miRNA microarrays
Total  RNA  was  pooled  from  groups  of  subjects  with 
similar clinical profiles from the larger cohort. This was 
done  to  generate  sufficient  RNA  for  labeling  and  the 
average clinical profile of the subjects that contributed to 
the  miRNA  analysis  can  be  found  in  Table  S1  in 
Additional file 1. Each sub-pool was >2 μg and 4 inde-
pendent  miRNA  profiles  per  clinical  subgroup  were 
created (resulting in a total of 16 independent miRNA 
determinations per clinical condition). The microarrays 
were miRCURY™ v10.0 LNA miRNA array from Exiqon 
(Vedbaek, Denmark). The Exiqon probe set consists of 
1,700  custom  made  capture  probes  that  are  enhanced 
using  locked  nucleic  acid  (LNA)  technology,  which  is 
claimed to normalize the Tm of the capture probes, as 
insertion of one LNA molecule into the capture probes 
increases  the  Tm  by  2  to  8°C.  Total  RNA  (2  μg)  was 
labeled  with  Hy3  dye  according  to  the  manufacturer’s 
protocol  using  the  labeling  kit  from  Exiqon.  For  the 
labeling reaction, RNA was incubated with the Hy3 dye, 
labeling enzyme and spike-in miRNAs, in a total volume 
of 12.5 μl, for 1 hour at 16°C. The enzyme was then heat-
inactivated  at  65°C  for  15  minutes.  The  samples  were 
incubated at 95°C for 2 minutes, protected from light. A 
total of 32.5 μl of hybridization buffer was added to make 
up the volume required by the hybridization station. The 
samples were briefly spun down and filtered through a 
0.45-micron  durapore  filter  (Millipore,  Billerica,  USA). 
Samples  were  then  loaded  onto  the  MAUI  (BioMicro 
Inc., Salt Lake City, UT, USA) hybridization station. The 
arrays were incubated at 56°C for 16 hours, then washed 
briefly in 60°C using buffer A, rinsed in buffer B, followed 
by a 2-minute wash in buffer B and a 2-minute wash in 
buffer C. The arrays were spun for 5 minutes at 1,000 rpm 
followed by immediate scanning using a GenePix 4200A 
microarray scanner. Data were analyzed using GenePix 
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entire chip, the distribution of intensities was plotted for 
all of the human annotated miRNA probes and this was 
compared  with  background  signal  intensities,  with  a 
cutoff of 400 units being taken as an expressed miRNA 
(total  of  171  human  miRNAs).  Differential  expression 
was  determined  using  the  significance  of  microarray 
analysis  (SAM)  approach  and  miRNAs  with  a  false 
discovery rate (FDR) of 10% or better and modulated by 
>30% were selected for further validation studies. Quan-
tile normalized raw data can be found in Additional file 2. 
Changes  were  verified  using  the  Applied  Biosystems 
TaqMan  assays  (Applied  Biosystems,  Foster  City,  CA, 
USA) on individual patient samples (Table S1 in Additional 
file 1; n = 10 for each patient group) and pooled RNA for 
Northern blots (where stated).
Real time quantitative PCR detection of mature miRNAs in 
skeletal muscle
Individual  muscle  RNA  samples  from  30  subjects 
(Table S1 in Additional file 1) were used for detection of 
individual miRNA expression. Subjects were matched to 
have  identical  age,  BMI  and  maximal  oxygen  uptake 
(VO2max); note that we profiled only non-obese subjects 
for  resource  reasons.  The  Taqman®  MicroRNA  assay 
(Applied Biosystems), which detects mature miRNA, was 
used  to  measure  miR-1  (Cat#4373161),  miR-133a 
(Cat#4373142), miR-133b (Cat# 4373172) and miR-206 
(Cat#4373092).  The  assay  relies  on  a  miRNA-specific 
looped primer for the reverse transcription (RT) reaction, 
which extends the mature miRNA sequence and enables 
detection in the subsequent Taqman assay. It is possible 
for the RT step to amplify the closely related pre-miRNA 
sequence. However, in competition with a more efficiently 
amplified,  primer  extended  mature  miRNA,  an  insigni-
ficant contribution from the pre-miRNA to the real time 
PCR signal is expected (approximately 1 to 5%) [44,45].
For each miRNA RT-PCR reaction, 5 ng of total RNA 
was reverse transcribed using the TaqMan® MicroRNA 
Reverse Transcription Kit (Applied Biosystems, PN4366597) 
and miRNA-specific primers. For quantitative real-time 
PCR (qPCR) the TaqMan® 2X Universal PCR Master Mix 
No  AmpErase®  UNG  was  used  (Applied  Biosystems, 
PN4324020). The samples were run on a 7900 Fast Real-
Time  PCR  System  (Applied  Biosystems)  on  the  9600 
emulation  mode  in  triplicates  of  10  µl  per  well.  The 
miRNA expression levels were normalized to the small 
nuclear RNA RNU48 (Cat#4373383), which appears not 
to  vary  between  subject  samples  for  human  skeletal 
muscle  (using  18S  as  a  comparator  for  RNU48).  All 
reactions were run single-plex in triplicate and quantified 
using the ΔCt method. Data are analyzed using ANOVA 
to compare differences in ΔCt values between the three 
groups followed by a post hoc t-test where appropriate to 
identify specific group differences. For all analyses P < 0.05 
was  considered  significant.  Statistical  calcula  tions  were 
performed using SPSS (SPSS Inc, Chicago, IL, USA) or 
Sigmastat (Systat Software Inc, San Jose, CA, USA).
Detection of pri-miRNA expression using SYBR green qPCR
To determine if pri-miRNA transcript abundance differs 
across  the  presumed  polycistronic  mir-1/mir-133a  pri-
miRNA,  we  utilized  qPCR.  Reverse  transcription  was 
performed on 1 µg RNA in a reaction volume of 40 µl 
using the high capacity cDNA reverse transcription kit 
(Applied  Biosystems)  and  random  hexamers.  The  RT 
reaction  was  run  at  25ºC  for  10  minutes,  37ºC  for 
120  minutes,  and  85ºC  for  5  s.  SYBR  green  reagents 
(Applied Biosystems) were used for detection of the pri-
miRNA  transcripts.  Primers  were  designed  to  amplify 
the  genomic  region  near  the  pre-miRNA  hairpin  to 
determine whether ‘neighboring’ pri-miRNAs are expressed 
in  a  similar  manner.  Primer  sequences  are  listed  in 
Table  S2  in  Additional  file  1.  Primer  efficiency  was 
established by plotting a standard curve of Ct values from 
serial  dilutions  of  cDNA  and  these  were  similar  in  all 
cases. Each qPCR reaction was prepared using 6 µl SYBR 
green mastermix, 4.6 µl nuclease-free H2O, 30 nM forward 
primer, 30 nM reverse primer and 1.2 µl of a 1:10 cDNA 
dilution in a total volume of 10 µl. The PCR reaction was 
run on an Applied Biosystems 7900 Fast Real-Time PCR 
system in standard mode, 10 minutes at 95ºC, then 45 
cycles consisting of 15 s at 95ºC and 60 s at 60ºC. Ct 
values  for  triplicates  were  averaged  and  ΔCt  values 
computed using 18S as the control.
Northern blot to detect pre- and mature miRNA}
To  enable  detection  by  Northern  blotting,  RNA  was 
pooled from each of the three groups above to provide 
independent  pools  of  10  µg  of  total  RNA.  An 
oligonucleotide was synthesized to probe for miR-133a/b 
(5’-AGCUGGUUGAAGGGGACCAAA-3’). A small RNA 
blot was prepared using a 15% denaturing gel, consisting 
of 15 ml SequaFlowGel sequencing system concentrate, 
7.5 ml SequaFlowGel diluent, 2.5 ml 10× MOPS buffer, 
250 µl 10% ammonium persulfate (Sigma, Poole, Dorset, 
UK)  and  25  µl  tetramethylethylenediamine.  RNA  was 
dissolved in 2× formamide loading dye, incubated at 95ºC 
for 2 minutes and loaded onto the gel along with Decade 
Marker (AM7778, Applied Biosystems). The gel was pre-
heated and then run at 100V for 3 hours using the WB 
system (Invitrogen) with 1× MOPS/NaOH (20 mM, pH 
7.0)  running  buffer.  The  RNA  was  transferred  to  a 
HybondN  neutral  membrane  (Amersham  Biosciences, 
Little  Chalforn,  Bucks,  UK)  by  applying  a  current  of 
400 mA for 1 to 1.5 hours. For chemical cross-linking 
[46] the membrane was incubated at 55ºC for 2 hours in a 
cross-linking solution consisting of 9 ml RNase free water, 
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EDC  (N-Ethyl-N’-(3-dimethylaminopropyl)carbodiimide 
hydrochloride). After membrane incubation at 37ºC for 
1 hour in a pre-hybridization mix (12.5 ml formamide, 
6.25 ml SSPE (20×), 1.25 ml Denhardt (100×), 1.25 ml 
10% SDS and 500 µl herring sperm (hs)DNA (2 mg/ml)) 
hybridization  occurred  overnight  in  a  solution  of  1  µl 
50 µM oligo, 11 µl nuclease-free water, 2 µl 10× buffer, 
2 µl RNase inhibitor, 2 µl T4 PNK (polynucleotide kinase) 
and 2 µl  32P-j-ATP that had been incubated at 37ºC for 
1 hour and filtered through a G-25 column. The membrane 
was  then  washed  twice  in  2×  SSC  and  0.1%  SDS  for 
1.5 hour at 65ºC and hybridization was detected by Kodak 
photographic  film.  The  membrane  was  subsequently 
stripped and re-probed for tRNA as a loading control.
miRNA knockdown and western blot analysis in C2C12 
myoblasts
C2C12 cells were seeded at 50% confluency in Dulbecco’s 
modified  Eagle’s  medium  (DMEM)  and  10%  fetal  calf 
serum (FCS). Before transfection cells were transferred to 
the serum and antibiotic free medium Optimem (Invitro-
gen), and transfected with 100 nM LNA miRNA inhibi-
tors  or  scrambled  oligo  (Exiqon)  with  Oligofectamine 
(Invitrogen) following the manufacturer’s protocol. Four 
hours after the transfection, FCS was added back to a 
final concentration of 8%. After 48 hours the cells were 
lysed, and RNA and protein were isolated and retained 
for  further  analysis.  Cells  were  lysed  by  boiling  in 
Laemmli  buffer  for  5  minutes.  Insoluble  material  was 
removed by centrifugation and protein content quantified 
using  the  BCA  reagent  (Pierce,  Little  Chalforn,  Bucks, 
UK). Proteins were size fractionated by SDS-PAGE using 
a 4 to 12% gradient bis-Tris NuPage gel (Invitrogen) and 
transferred onto a nitrocellulose membrane (Whatman, 
Little Chalforn, Bucks, UK). The efficacy of the transfer 
was examined by Ponceau Red staining of the membrane. 
The  membrane  was  blocked  by  incubation  at  room 
tempera  ture with a solution of 5% skimmed milk in Tris-
buffered  saline  (TBS),  0.2%  Tween,  0.05%  Triton  X100 
(TBST)  or  5%  bovine  serum  albumin  (BSA)  in  TBST. 
Incubation with primary antibody anti-PTBP1 (Polypyri-
midine tract-binding protein 1; Proteintech Group Inc. 
(Chicago, Illinois, USA) at 1:1,000 in 5% skimmed milk/
TBST  or  anti-CDC42  (Cell  Signaling  Technology, 
Danvers, MA, USA) at 1:1,000 in 5% BSA/TBST) took 
place overnight at 4ºC. Blots were washed and incubated 
with  an  anti-rabbit  IgG  horse  radish  peroxidase- 
conjugated antibody (1:5,000; Cell Signaling Technology) 
for  1  hour  at  room  temperature.  Specific  signal  was 
detected  using  the  ECL  reagent  (GE  Healthcare,  Little 
Chalforn, Bucks, UK) and exposure on Kodak BioLight 
film. An image of the Ponceau membrane and each blot 
were analyzed using the ImageJ software (NIH). The area 
under the curve for each blot signal was corrected for 
protein loading using the area under the curve from the 
Ponceau  signal.  These  loading  corrected  signals  were 
then  scaled  to  the  signal  for  the  cells  transfected  with 
scrambled  sequence  and  percentage  changes  in  signal 
were  calculated.  A  minimum  of  two  independent  cell 
transfections were carried out.
Muscle tissue western blot analysis
Human  muscle  samples  were  homogenized  (n  =  13) 
using a Tissue-lyser (Qiagen, Crawley, West Sussex, UK) 
in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 
1 mM EDTA, 0.25% NaDeoxycholate, 1% Triton X-100. 
Phosphatase inhibitor cocktail 1 and 2 (Sigma Aldrich, 
Poole, Dorset, UK) and protease inhibitor complete mini 
(Roche,  Welwyn  Garden  City,  Hertfordshire,  UK)  was 
added to the buffer immediately before homogenization. 
Following homogenization, protein lysates were centri-
fuged at maximum speed for 1 hour at 4°C and the pellet 
was  discarded.  Protein  concentration  was  measured 
using a Bio-Rad protein assay. Samples were diluted in 5× 
Laemmli  buffer  and  boiled  for  2  minutes  before 
subsequent loading of 25 µg onto a 4 to 12% gradient bis-
Tris  NuPage  gel  (Invitrogen).  The  gel  was  run  for 
120 minutes at 125V and protein was transferred onto a 
PVDF membrane using a semi-dry blotting system for 
2 hours at 20V (Invitrogen). The membrane was blocked 
for  1  hour  at  room  temperature  in  5%  skimmed  milk. 
Incubation with primary antibody took place overnight 
at 4ºC. Antibody dilutions were: anti-PTBP1 at 1:4,000 in 
5%  skimmed  milk/TBST;  anti-CDC42  at  1:4,000  in  5% 
BSA/TBST; anti-HOXA3 (Abnova, Walnut, CA, USA) at 
1:2,000 in 5% milk; anti-HOXC8 (Abnova) 1:1,000 in 5% 
milk;  anti-BIM  at  1:2,000  in  5%  BSA;  and  anti-BDNF 
(Brain-derived  neurotrophic  factor;  Santa  Cruz,  Santa 
Cruz,  CA,  USA)  at  1:200  in  0.25%  BSA.  Blots  were 
washed and incubated with anti-rabbit or anti-mouse IgG 
horse radish peroxidase-conjugated antibody (1:2,000; Cell 
Signaling  Technology)  for  1  hour  at  room  temperature. 
The  signal  was  detected  using  Supersignal  West  Femto 
Luminal/Enhancer Solution (Thermo Scientific, Waltham, 
MA, USA) and subsequent exposure in a charge-coupled 
device camera (Bio-Rad, Hemel Hempstead, Hertfordshire, 
UK). Following exposure, blots were briefly rinsed in TBST 
and  then  incubated  in  0.5%  Reactive  Brown  (Sigma 
Aldrich)  for  15  minutes.  Blots  were  analyzed  and 
quantified using ImageQuant (Amersham, Little Chalfont, 
Bucks, UK) software, with the reactive brown image as a 
control for equal loading and transfer.
Human muscle satellite cell isolation, proliferation and 
differentiation
Satellite cells were isolated from vastus lateralis muscle 
biopsies as previously described [47]. Briefly, following 
Gallagher et al. Genome Medicine 2010, 2:9 
http://genomemedicine.com/content/2/2/9
Page 5 of 18removal  of  fat  and  connective  tissue,  the  biopsy  was 
digested in a 10 ml buffer containing trypsin and collage-
nase  II  for  5+10  minutes.  To  minimize  fibroblast 
contamination, cells were pre-seeded in a culture dish for 
3  hours  in  F10/HAM,  20%  FBS,  1%  penicillin/strepto-
mycin (PS), 1% Fungizone. Unattached cells were then 
removed and seeded into a culture flask, pre-coated with 
matrigel (BD Biosciences, San Jose, CA, USA). Following 
4  days  of  incubation,  the  cell  culture  medium  was 
changed  and  then  every  second  day  thereafter.  Cell 
cultures were expanded and then seeded for proliferation 
or  differentiation.  For  proliferation,  satellite  cells  were 
seeded into culture dishes pre-coated with matrigel (BD 
Biosciences).  Cell  culture  medium  was  changed  to 
DMEM low glucose, 10% FBS, 1% PS. Cells were allowed 
to become 75% confluent and then harvested in cell lysis 
buffer  (Cell  Signaling  Technology).  For  differentiation, 
the  cell  culture  medium  was  changed  to  DMEM  low 
glucose,  10%  FBS,  1%  PS  and  cells  were  allowed  to 
become  completely  confluent.  When  the  satellite  cells 
started to change morphology and line-up, the medium 
was changed to DMEM high glucose, 2% horse serum, 
1% PS. At day 5 on low serum, myotubes were formed 
and  harvested  in  cell  lysis  buffer  (Cell  Signaling 
Technology).
miRNA target prediction and Gene Ontology analysis
The binding of miRNA to target mRNA occurs between 
the ‘seed’ region of the miRNA (nucleotides 2 to 7 of the 
5’  end  of  the  mature  miRNA)  and  the  3’  untranslated 
region of the mRNA. Gene lists of predicted targets for 
each modulated miRNA were obtained using TargetScan 
4.2  [48].  Several  groups  have  used  microarray  data  to 
examine the expression changes when a single miRNA 
changes,  and  we  used  the  mean  absolute  expression 
approach described recently by Arora and Simpson [49] 
and also the tissue-centric approach described by Sood et 
al. [50] to determine whether we could detect shifts in the 
average expression of mRNA targets of the muscle-specific 
miRNAs  (miR-1,  miR-133a/b  and  miR-206,  collectively 
known as ‘myomirs’) in human skeletal muscle. We found 
no evidence of systematic mRNA changes.
We thus set out to generate a new method of predicting 
which  genes  should  be  altered  in  the  face  of  multiple 
changes  in  miRNA  concentration.  The  development  of 
ranking procedure is described in detail within the results 
section. We used Gene Ontology analysis [51] to obtain 
an overview of the functions of predicted gene lists and 
select protein targets for further evaluation in cell culture 
and  tissue  samples.  For  Gene  Ontology  analysis  we 
filtered  predicted  gene  target  lists  using  tissue-specific 
gene  expression  profiles  derived  from  U133a+2  Affy-
metrix chip data (n = 118). We also utilized the global 
muscle transcriptome as the background RNA expression 
data set, as misleading ontological enrichment P-values 
are yielded when a generic (genome-wide) reference data 
set is utilized.
Results
Global transcription in skeletal muscle is unaltered in type 
2 diabetes
Simple hierarchical clustering and scatter plots of ‘gene 
sets’ were used to explore the dataset. As can be seen 
from Figure S2 in Additional file 1 global clustering by 
subject (n = 118) resulted in a plot that distributed healthy 
controls  (normal  glucose  tolerance  (NGT),  black-bar), 
impaired glucose tolerance (IGT, yellow-bar) and patients 
(T2D,  red-bar)  across  the  data  set,  with  no  obvious 
grouping  of  subjects  and  was  not  dependent  on  the 
normalization method (data not shown). The Affymetrix 
data were then analyzed using SAM [52] and limma in R 
[53]. No significant differences in individual gene expres-
sion were found between the subject groups with either 
method.  To  further  test  this  conclusion,  we  utilized  a 
quantitative correlation analysis approach whereby each 
individual gene’s expression was related to fasting glucose 
and fasting insulin. This correlation analysis is a logical 
approach, as the threshold when a patient is diagnosed 
with T2D is pragmatic, driven by categorization of risk to 
aid  medical  treatment.  Quantitative  SAM  analysis 
produces a FDR for genes that positively and negatively 
correlated with these two markers of clinical status. A 
modest number of genes (approximately 50) were found 
to correlate significantly with fasting glucose (FDR = 5%) 
and  even  fewer  with  insulin  levels  (approximately  10). 
However, the correlation coefficients were very modest; 
gene expression values covered approximately 90% of the 
range for insulin or glucose and thus can be deemed of 
limited  biological  significance  (limma  based  analysis 
found  even  fewer  genes).  Thus,  gene  chip  analysis 
indicates that T2D and muscle insulin resistance are not 
associated  with  global  changes  in  mRNA  abundance, 
despite the sensitivity of the technology [18-20]. We ran 
two  smaller  human  skeletal  muscle  studies  [20]  at  the 
same  core-lab  and  both  yielded  substantial  (1,000  to 
3,000)  differential  expression  using  the  same  methods 
and staff. Given this, and the larger sample size of this 
diabetes study, and the substantial difference in insulin 
resistance (Table 1), the lack of global mRNA changes in 
T2D appears convincing.
Mitochondrial related transcript abundance is not 
associated with insulin resistance
Another  approach  to  improve  statistical  power  is  to 
select  a  small  subset  of  genes  on  the  gene  chip  for 
analysis. For example, on the Affymetrix gene chip, >400 
genes  are  annotated  as  carrying  out  mitochondrial 
related functions; this list of genes has been called the 
Gallagher et al. Genome Medicine 2010, 2:9 
http://genomemedicine.com/content/2/2/9
Page 6 of 18‘OXPHOS’ gene set [1]. We plotted the expression of the 
OXPHOS  gene  set  in  NGT  versus  T2D  subjects 
(Figure 1a) and the OXPHOS mRNAs fell on the line of 
equality,  indicating  no  differential  expression.  We  then 
investigated if a physiological parameter may explain the 
difference between our study and that of Mootha. We did 
this  by  creating  a  subgroup  of  patients  (Table  S3  in 
Additional file 1) where the control subjects (n = 14) had 
a lower BMI and a higher aerobic capacity than the T2D 
subjects (n = 17) - that is, less well matched - similar to 
the Mootha et al. study. Again, we found no alteration in 
OXPHOS  gene  expression  (Figure  1b).  Furthermore, 
there is no correlation between OXPHOS gene expres-
sion and HOMA1 (Figure 1c) or HOMA2 expression, or 
Figure 1. OXPHOS gene expression and relationship to disease status. (a) Plot of median intensity of OXPHOS probes (red circles) for NGT 
(n = 47) versus T2D (DM; n = 45) on the background of absent filtered probesets (black circles). The insert shows the mean expression of OXPHOS 
probesets (± standard error of the mean). (b) Plot of median intensity of OXPHOS probes (red circles) for NGT (n = 14) versus T2D (n = 17) on the 
background of absent filtered probesets (black circles). These subjects have the same physiological characteristics as those in the Mootha et al. 
study [1]. The insert shows the mean expression of OXPHOS probesets (±standard error of the mean). (c) Correlation plot for HOMA2 insulin 
resistance (IR) and MAS 5.0 normalized expression values for the OXPHOS probe sets. Each point represents the median expression for an OXPHOS 
probe set after filtering the Affymetrix data as described above. The subject groups are represented by colored points: black = normal glucose 
tolerance; green = impaired glucose tolerance; red = type 2 diabetic. The regression line is shown in black along with the R squared value for 
goodness of fit and the P-value indicating significance of the relationship. (d) The linear correlation between 2 hour blood glucose (during oral 
glucose tolerance test) and PGC-1α expression (n = 118) in skeletal muscle of subjects across the clinical groups NGT (black-dots), IGT (green-dots) 
and T2D (red-dots) derived from the Affymetrix probe set. The regression line is shown in black along with the R squared value for goodness of fit 
and the P-value indicating significance of the relationship.
(a) (b)
(c) (d)
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coactivator-1α  (PGC-1α)  and  plasma  glucose  concen-
tration (Figure 1d).
We then used a more powerful statistical method, gene 
set enrichment analysis (GSEA), using both the original 
[1] and adapted versions of GSEA and their respective 
‘gene sets’ [54]. While we could reproduce the results of 
Mootha  et  al.  using  their  clinical  samples  and  both 
methods, when we examined our larger data set, no gene 
set was enriched (using the original and latest C2.all.v2.5 
list).  OXPHOS  related  gene  sets  (six  such  lists  are 
included with the program) appeared distributed across 
the list of enriched genes in control subjects (ranked at 
positions 8, 14, 57, 66, 370 and 391) and none were statis-
tically significant. Finally, we ran GSEA on the subgroup 
that re-created the patient characteristics of the Mootha 
et  al.  study  and  found  that  the  ‘Mootha_VOXPHOS’ 
gene-set  had  a  FDR  of  96%.  The  only  remaining 
distinguishing  feature  we  are  aware  of,  between  these 
studies, is the 3 hour pharmacological insulin infusion 
protocol utilized by Mootha et al. prior to biopsy sampling 
(see Discussion). Thus, based on analysis of the largest 
available  human  muscle  T2D  array  data  set,  we  can 
conclude  that  there  are  no  robust  changes  in  protein-
coding mRNAs in the skeletal muscle of diabetes patients 
(although this does not rule out subtle changes in splice 
variants). The analysis suggests that a post-transcriptional 
mechanism should exist to regulate the development of 
insulin resistance in T2D patients, so we tested the hypo-
the  sis  that  altered  miRNA  expression  occurs  and  in  a 
manner that relates to the development of insulin resistance.
Analysis of global diabetes-induced changes in skeletal 
muscle miRNA expression
We  detected  approximately  170  human  miRNAs  in 
skeletal muscle tissue, consistent with muscle expressing 
a  large  number  of  miRNA  species.  Twenty-nine  were 
significantly up-regulated by >1.3-fold (FDR <10%), while 
33 were down-regulated by >1.3-fold (FDR <10%) in T2D 
(Additional file 2). Taking the miRNAs that were differen-
tially  expressed  in  patients  with  T2D,  we  then  plotted 
their  expression  and  included  the  impaired  glucose 
tolerance samples (Figure 2a). It was clearly evident that 
approximately  15%  of  up-regulated  and  approximately 
15% of down-regulated miRNAs were altered early in the 
disease process, while many changed progressively and a 
substantial minority were found to be altered only once 
the patients had diabetes (Figure 2a). By cross-referencing 
[18] gene chip data sets we identified that 11 from 61 
miRNAs demonstrate a pattern of change in expression 
(Figure 2b) that was the exact opposite of that observed 
during muscle differentiation [55]. As far as we are aware 
the only study of myocyte differentiation, in the context 
of  diabetes,  derives  from  streptozotocin-diabetic  rats, 
where  primary  muscle  from  diabetic  animals  fails  to 
robustly fuse to form multinucleated myotubes in vitro 
[56]. Since we observed an inverse relationship between 
‘muscle development’ miRNAs and changes in diabetes, 
we further investigated the reason for altered expression 
of the muscle specific miRNAs.
Muscle-specific mature miRNAs are down-regulated in 
type 2 diabetes
Mature  myomirs  were  measured  in  skeletal  muscle 
biopsies from three different groups (Table S1 in Addi-
tional file 1; T2D, n = 10; IGT, n = 10; and NGT, n = 10). 
ANOVA indicated that miR-133a (F = 11.8, P < 0.0001) 
was  significantly  different  between  the  three  groups, 
miR-206  expression  more  modestly  altered  (F  =  4.5, 
P  =  0.02)  and  miR-1  and  miR-133b  were  unchanged 
(Figure  2c).  Northern  analysis  was  used  to  document 
differ  ences  in  precursor  miR-133  and  mature  miR-133 
abundance. The Northern probe detects both miR-133a 
and  miR-133b  due  to  sequence  similarity.  The  steady 
state level of pre-miR-133 was very low in human skeletal 
muscle  compared  with  the  signal  from  the  mature 
miR-133a/b  expression  transcript  (Figure  S3  in 
Additional file 1). This confirms that along with the much 
lower (>100 times) amplification efficiency [45], miR-133 
pre-miRNA cannot contribute to the TaqMan signal.
Skeletal muscle miR-133a expression was reduced by 
five-fold in T2D (P < 0.001). A clear stepwise reduction in 
mature  miR-133a  expression  was  observed  across  the 
three  clinical  groups.  We  found  that  expression  of 
miR-133a was associated with fasting glucose and 2 hour 
glucose tolerance data (R2 = 0.37, P < 0.001), with higher 
fasting  glucose  levels  associated  with  lower  miR-133a 
expression (Figure 2d). In addition, miR-133a expression 
was significantly associated with HbA1c, an indicator of 
long-term glucose homeostasis (R2 = 0.29, P < 0.01) and 
also correlated with HOMA1 (R2 = 0.15, P = 0.04). A total 
of six correlations were carried out and the P-values are 
unadjusted.  Subsequently,  we  checked  miR-206,  which 
associated more modestly with these clinical parameters, 
and miR-1, which did not associate with any of these clinical 
parameters.  Thus,  we  found  that  altered  miR-133a 
expression  modestly  related  to  important  clinical  para-
meters. We then investigated if the altered steady-state level 
of mature miR-133a was a consequence of failure to produce 
the primary RNA transcript in the nucleus (Figure S3B in 
Additional  file  1).  As  the  pri-miRNA  abundances  were 
unchanged,  altered  processing  or  degradation  appears 
responsible  for  the  loss  in  selective  myomir  expression 
rather than altered transcription.
Detection of miRNA-133a target protein in vitro and in vivo
There was no change in the mRNA expression of genes 
that  contained  myomir  target  sites  (data  not  shown); 
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than mRNA cleavage. Using western blotting, we exam-
ined  if  loss  of  myomir  expression  could  detectably 
increase protein targets in a muscle cell model. CDC42 
and PTBP1 were selected for study because they ranked 
highly as targets of miR-133/miR-206 in the TargetScan 
database and both proteins are relevant for muscle cell 
differentiation  and  metabolism  [57,58].  Interestingly, 
reduction in miR-133a using an antagomir (Figure S4A in 
Additional  file  1)  had  an  indirect  effect  on  the  other 
myomirs, such that miR-133b (expected due to sequence 
similarity) and miR-206 (unexpected) were substantially 
reduced.  This  altered  expression  pattern  of  mature 
myomirs was not associated with substantial changes in 
pri-miRNA expression (Figure S4B in Additional file 1), 
suggesting  some  degree  of  physiological  feedback  on 
miRNA maturation during the use of a so-called ‘selective’ 
antagomir [59]. Western analysis of CDC42 and PTBP1 
demonstrated  expected  increases  (approxi  mately  37% 
and  20%,  respectively)  in  protein  expression  following 
antagomir  treatment  (Figure  S4C  in  Additional  file  1), 
confirming the suitability of antibodies against them for 
in vivo profiling.
In contrast, analysis of CDC42 and PTBP1 proteins in 
muscle  tissue  provided  no  evidence  that  these  targets 
were  altered  in  vivo  (n  =  7  to  8  subjects  per  group; 
Figure 2. miRNA expression profile changes in T2D compared with control subjects using the Exiqon chip platform and TaqMan 
confirmation (FDR <10%). (a) Data are plotted to show the pattern of change of these significantly up-/down-regulated miRNA. Black lines 
represent those miRNA that increase/decrease progressively with IGT and T2D (DM), green lines represent miRNAs that are increased/decreased 
with IGT and then revert with T2D, while orange lines show miRNAs increased/decreased only in the T2D state. (b) miRNAs that show the 
expression profile during myocyte differentiation (cell data derived from Chen et al. [55]) is the opposite pattern to that observed in the muscle of 
patients with T2D (green = down-regulated probe sets, red = up-regulated probe sets; the color range is from -3-fold to +3-fold change). MG refers 
to the data produced by Chen et al. during myogenesis. (c) Expression level of miR-1, miR-133a, miR-133b and miR-206 in muscle biopsies from 
healthy individuals (NGT, n = 10, white bars), individuals with impaired glucose tolerance (IGT, n = 10, grey bars) and individuals with type 2 diabetes 
(T2D, n = 10, black bars). miR-133a (P < 0.001) and miR-206 (P = 0.04) were significantly reduced in T2D patients when compared with expression 
levels in healthy controls. Data are expressed as fold change from NGT and shown as mean ± standard error. **P < 0.001, *P < 0.05. (d) Expression 
level of miR-133a in muscle versus indices of glucose homeostasis in subjects with and without T2D. Expression of miR-133a is positively correlated 
with fasting glucose, R2 = 0.41 (P < 0.001, n = 30). Data are shown as ΔCt levels normalized to RNU48 and plotted versus fasting glucose levels (mmol/L).
(a) (b)
(c) (d)
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studies  documenting  the  first  global  analysis  of  the 
relationship between miRNA and the proteome [23,24] 
found that altered expression of single miRNAs typically 
had a modest impact on individual protein expression, 
suggesting  to  us  that  the  collective  changes  in  many 
miRNAs may be the most biologically interesting para-
meter to consider. Thus, we hypothesized that the most 
likely  scenario  is  that  groups  of  miRNAs  work  co-
operatively in vivo, and that physiological regulation of a 
single muscle protein by a single miRNA may be a rather 
rare occurrence [60]. It is with this in mind that we set 
about  developing  a  new  ranking  system  (Figure  S1  in 
Additional file 1) for altered tissue miRNA expression to 
help define the biochemical consequences of the altered 
expression  of  the  approximately  60  miRNAs  in  T2D. 
Interestingly,  our  new  analysis  procedure  subsequently 
identified CDC42 and PTBP1 as being equally targeted 
by  both  up-  and  down-regulated  miRNAs  (Additional 
file 2); thus, CDC42 and PTBP1 should not be altered in 
vivo by diabetes (as we demonstrated by western blotting 
prior to developing our ranking metric).
A novel weighted context score ranking analysis of global 
changes in diabetes-induced changes in miRNA expression
Even a modest reduction in protein content can, if within 
a  single  canonical  pathway,  have  a  strong  impact  on 
physiological function. With this in mind, we hypothe-
sized that the main biological consequence of multiple in 
vivo miRNA changes may reflect the collective targeting 
of multiple members of selected signaling pathways. The 
collective ‘activity’ must reflect the observation that both 
up-regulated and down-regulated miRNA can target the 
same  genes  such  that  the  biological  impact  cannot  be 
assessed  using  single  miRNA-target  associations.  We 
devised a ranking system using the conserved target site 
criteria from the TargetScan database (which is able to 
significantly  enrich  a  gene  population  in  validated 
3’ targets [34]) and combined this with our tissue-specific 
gene and miRNA expression data (Figure S1 in Additional 
file 1). Evaluation of the ranking procedure was carried 
out  through  the  identification  of  statistically  enriched 
and biologically validated gene ontologies and canonical 
signaling  pathways,  following  adjustment  for  multiple 
comparison testing, in the most targeted compared with 
the  least  targeted  genes.  Such  an  approach  was  viable 
using the TargetScan database as we require the context 
scoring metric as an input for the weighted cumulative 
context ranking score (wCCS) procedure. An R-script is 
included (Additional file 2).
Present-marginal-absent call filtering is able to identify, 
with  reasonable  sensitivity  [42],  which  mRNAs  are 
expressed  in  muscle.  This  list  of  approximately  20,000 
probe  sets  was  cross-referenced  with  the  TargetScan 
database of miRNA target genes for the 62 T2D miRNAs 
(approximately 9,000 genes), identifying a total of approxi-
mately  4,700  muscle  expressed  genes  with  conserved 
miRNA targets sites for the diabetes-modulated miRNAs. 
Each target site, on each gene, has a distinct context score 
relating to the likelihood that a given miRNA will inhibit 
protein  translation  or  cause  mRNA  cleavage  [25]. 
Summation of these scores provided us with a range of 
gene-specific  cumulative  context  scores  (CCS)  with  a 
distribution  shown  in  Figure  S5A  in  Additional  file  1. 
First quartile ranked mRNAs tended to be expressed at a 
lower  median  intensity  than  fourth  quartile  targeted 
genes in control subjects (Figure S5B in Additional file 1), 
suggesting  miRNA-mediated  suppression  of  mRNA 
abundance or co-evolution of tissue-specific expression. 
Yet, when tested, we found no association between these 
miRNA target mRNAs and abundance across the clinical 
groups (Figure S5C,D in Additional file 1), which is in 
agreement with our Affymetrix analysis. Indeed, convinc-
ing evidence that mRNA cleavage occurs in mammalian 
cells originates from studies where very large changes in 
a  single  miRNA  are  created  by  transfection  or  knock-
down and this may not be relevant in vivo.
We  further  reasoned  that  the  net  effect  of  the  up-
regulated (n = 29) and down-regulated (n = 33) miRNAs 
on a particular gene would be a product of the change in 
miRNA  expression  and  the  CCS.  To  model  this  we 
adjusted  each  target  site  context  score  by  the  diabetes 
related changes in miRNA expression to provide a wCCS. 
The upper quartile of up- and down-regulated diabetes 
miRNA targeted genes (first quartile wCCS genes) yields 
two  overlapping  gene  lists,  where  approximately  270 
targets are common to both lists (Figure 3a). We summed 
the wCCS for the common 270 genes, taking direction of 
change into account, and for the majority of cases the 
wCCS for the up-regulated miRNA targets equaled the 
wCCS for the down-regulated miRNA targets (suggesting 
we should expect no net impact on protein expression, 
for  example,  for  PTBP1).  However,  for  approximately 
10%  of  overlapping  genes  the  wCCS  was  sufficiently 
strong such that the gene was retained in either the first 
quartile up- or down-regulated list.
Validation of the weighted CCS ranking procedure by 
ontological and pathway analysis
Ontological analysis is complex and for analysis of these 
wCCS adjusted target lists we combined the two, non-
overlapping (Figure 3a) lists to explore the targeted bio-
logical processes. We did this using the muscle-specific 
transcriptome as the background file (use of the entire 
genome  is  inappropriate,  as  the  muscle-specific  trans-
criptome is already highly enriched in ontologies). Highly 
significant  enrichment  was  uniquely  found  within  the 
first  quartile  of  ranked  genes,  including  metabolic 
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Page 11 of 18(P < 7.4 × 10-8), post-translational modification (P < 9.7 × 
10-5) and  developmental  (P  <  1.3  ×  10-6)  processes  (all 
Benjamini-Hochberg  adjusted).  Further  analysis,  using 
only the predicted target list as background (to establish 
if  those  genes  with  the  highest  wCCS  contribute  to 
unique bio  logical activities beyond the ontological profile 
of the entire miRNA mRNA target list) retained tissue 
develop  ment,  and  more  specifically  homeobox  gene 
modulation, as a significant feature (FDR <5%). The 4th 
quartile of conserved wCCS targets did not demonstrate 
such  enrichment  (Additional  file  2).  Given  that  the 
mRNA  trans  criptome  was  invariant  and  the  proposed 
bio  chemistry  of  skeletal  muscle  insulin  resistance, 
modula  tion of post-translational and metabolic processes 
is a logical finding, while our analysis highlights muscle 
development,  possibly  regulation  of  muscle  stem-cell 
status, as being of potential importance.
Ontological enrichment of a target gene-list provides 
statistical evidence of distinct biological processes being 
targeted by the miRNAs that change in human diabetes, 
but it remains a further challenge to pinpoint the signal-
ing pathways involved in the disease process from these 
alone. To this end, canonical pathway analysis was used 
(based  on  Ingenuity  verified  interactions)  to  visualize 
whether  first  quartile  genes  belong  to  known  insulin 
resistance related processes. We found approximately six 
significant canonical pathways (Figure S6 in Additional 
file  1)  represented  within  our  first  quartile  wCCS  list; 
encouragingly,  these  represent  incompletely  described 
diabetes disease pathways. The highest ranked signaling 
pathway,  transforming  growth  factor-β  signaling,  is 
extensively  implicated  in  all  aspects  of  skeletal  muscle 
function  [61],  while  at  an  individual  gene  level,  the 
directional changes in ERK1/2 and MEK1/2 are consis-
tent  with  the  emerging  mechanism  through  which 
saturated fatty acids induce muscle insulin resistance [62] 
and with decreased IRS-1 (insulin receptor substrate-1) 
phosphorylation [63] promoting the degradation of IRS-1 
[64]  and  thus  impaired  insulin  action.  Furthermore, 
modulation  of  glucocorticoid  signaling  [65-67],  cAMP 
metabolism  [68-70]  and  BDNF  activity  [71-75]  are 
connected with insulin resistance in humans and various 
animal  models.  Thus,  the  novel  tissue-specific  wCCS-
based  analysis  of  the  62  miRNAs  altered  in  human 
diabetic  muscle  correctly  identified  diabetes-related 
disease  mechanisms,  providing  support  for  this  new 
method of functional annotation of in vivo global miRNA 
data sets. The fourth quartile of conserved wCCS targets 
did not demonstrate any canonical pathway enrichment 
above the level of chance. We recently produced a parallel 
miRNA  and  mRNA  profile  of  adipogenesis.  When 
applying the wCCS we again found ontological enrich-
ment in the first quartile versus fourth quartile ranked 
genes; >80% of the first quartile genes were not part of 
the diabetes miR target list and the ontological profile 
was distinct (data not shown).
Protein validation of the wCCS method
While the informatic validation of the ranking procedure 
was encouraging, it was important to provide evidence 
that  protein  abundance  changes  could  be  correctly 
predicted. As noted above, the wCCS correctly identified 
both  CDC42  and  PTBP1  protein  abundance  as  un-
changed  and  our  protein  analysis  confirmed  this.  We 
then examined the mRNA and protein expression of four 
additional  developmental  protein  targets  that  were 
predicted to be up-regulated either in the skeletal muscle 
tissue  (HOXA3,  BCL2L11  (also  known  as  BIM1)  and 
HOXC8) or, in the case of BDNF, in the skeletal muscle 
satellite cells. These targets were selected based on there 
Figure 3. Generation and validation of a weighted cumulative context score for type 2 diabetes miRNAs. (a) Target genes with a more 
negative cumulative context score (CCS) are, on average, expressed at a lower level than non-targeted genes (Additional file 2). To determine 
which genes are most targeted when there is a shift in global miRNA expression, the distribution of CCS was adjusted on a gene by gene basis for 
the magnitude of up-/down-modulation of [miRNA] - wCCS. As can be seen, despite the vast number of potential predicted targets (Figure S5A 
in Additional file 1), few target genes have highly scoring wCCSs. There were 279 genes in the first quartile predicted to be up-regulated (reduced 
regulation by miRNAs) and 355 in the first quartile predicted to be down-regulated (increased regulation by miRNAs). The composition of these 
lists was validated using pathway and ontology analysis (b). Consistent with the global Affymetrix analysis (Figure S2 in Additional file 1) the 
mRNA of developmental related first quartile wCCS genes was identical between patients and controls. This was true regardless of whether the 
gene should be up-regulated (BDNF, BCL2L11(BIM), HOXA3, HOXC8, HOXA7 and HOXB7), down-regulated (HOXC4), or unchanged (CDC42 and 
PTBP1). This indicates miRNA are operating to block protein translation. Error bars = s.e.m. (c) Proteins highly ranked for being up-regulated were 
selected and protein expression was analyzed in skeletal muscle biopsies from normal glucose tolerant controls (NGT; n = 6) and subjects with 
T2D (DM; n = 6). From a second set of subjects, satellite cells were isolated from skeletal muscle biopsies from normal glucose tolerant controls 
(NGT) (n = 5 to 6) and subjects with T2D (DM; n = 5 to 6). The satellite cells were harvested in a proliferative state or as differentiated into myotubes. 
Protein expression was analyzed by using western blotting and specific antibodies towards the protein targets. HOXA3 (top left) was detected as 
a 30 kDa band, significantly up-regulated in muscle from subjects with T2D (P = 0.006). BCL2L11 (BIM; top middle) was detected as a band around 
25 kDa, significantly up-regulated in muscle from subjects with T2D (P = 0.014). HOXC8 (top right) was detected as a band around 36 kDa and 
demonstrated a clear trend for up-regulation (P = 0.07). BDNF (bottom) was detected as a band at 14 kDa, up-regulated in proliferating satellite 
cells derived from subjects with T2D where it is typically expressed (p = 0.014) but was not expressed in differentiated satellite cells or adult muscle. 
* = P value < 0.05; ** = P value < 0.001.
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they appear near the top of the first quartile of the wCCS 
gene list. We noted that yet again there were no shifts in 
mRNA  abundance  of  these  target  genes  (Figure  3b). 
Convincingly,  we  demonstrated  that  HOXA3  and 
BCL2L11  proteins  were  up-regulated  by  approximately 
50%,  while  BDNF  was  also  up-regulated  (Figure  3c). 
HOXC8  expression  was  altered  less  markedly  but  there 
was a clear trend consistent with the prediction (P = 0.07). 
We also examined the Baek et al. [23] database of in vitro 
global  protein  changes  when  miRNAs  were  artificially 
manipulated in a HeLa cell system. Our wCCS ranking 
yielded  analysis  consistent  with  their  protein  level 
changes  (Additional  file  2).  Thus,  protein  analysis 
supported  the  validity  of  our  tissue-specific  wCCS 
ranking approach for interpretation of the consequences 
of multiple in vivo miRNA changes.
Discussion
The molecular processes contributing to skeletal muscle 
insulin  resistance  are  incompletely  understood  [76], 
while evidence that developmental factors may play a role 
is  accumulating  [77].  The  present  genome-wide  RNA 
analysis  presents  further  evidence  that  the  human 
skeletal muscle coding transcriptome in T2D is indistin-
guishable  from  that  of  control  subjects.  In  contrast, 
miRNA  profiling,  coupled  with  the  wCCS  analysis 
method,  indicates  approximately  one-third  of  muscle-
expressed  miRNAs  are  altered  in  diabetes  and  that 
collectively  these  miRNAs  target  established  diabetes-
related signaling pathways and highlight a potential role 
for developmental genes. This included BDNF, which was 
only expressed in satellite cells and this may be disease 
specific as it has been found to be unaltered by physical 
activity status in humans or rodents [18,73]. A seventh 
protein  (LIF)  was  validated  very  recently  in  our  lab. 
However,  wider  protein  level  validation  of  the  wCCS 
approach will require large scale sensitive proteomics, and 
this  is  not  an  easy  option  with  small  human  clinical 
samples  at  this  time.  Meanwhile,  targeted  protein 
profiling  of  highly  ranked  proteins  identified  by  our 
method  is  a  viable  alternative  for  studying  miRNA 
regulated protein networks. Establishment of additional 
parallel coding and non-coding transcriptome data sets, 
where  multiple  miRNA  families  are  simultaneously 
altered by disease or physiological stimuli, will provide 
opportunity to further refine the wCCS approach.
The invariant type 2 diabetes skeletal muscle mRNA 
transcriptome: experimental design considerations
A limitation of microarray technology is that it does not 
provide data on possible protein level changes. Never-
theless, if one wants to establish system-wide changes - 
on the understanding that complex phenotypes involve 
differential  regulation  of  gene  networks,  not  just 
individual  genes  -  then  microarrays  are  currently  the 
systems  biology  tool  of  choice.  In  contrast  to  the 
unchanged  global  transcriptome  in  insulin  resistant 
skeletal muscle, there are several observations that the 
expression  of  individual  mRNA  transcripts  display 
altered expression in the skeletal muscle of patients with 
T2D  on  a  gene-by-gene  basis.  However,  such  changes 
[78] do not correlate with disease severity and often are 
not  reproducible  in  larger  samples  [79].  Using  an 
appropriately  matched  cohort  approximately  ten  times 
the size of the Patti et al. study [2], we establish that the 
T2D  global  muscle  coding-RNA  transcriptome  is  in-
variant,  while  our  subgroup  analysis,  designed  to  be 
comparable  with  Mootha  et  al.  [1],  demonstrates  that 
their observation of a reduced OXPHOS gene set in T2D 
patients appears to reflect the acute differential response 
to pharmacological levels of insulin [80] in their control 
subjects, or some other confounding drug treatment in 
their diabetes patients (for example, statin therapy). This 
conclusion  is  in  agreement  with  recent  physiological 
studies  [11,81,82]  where  no  intrinsic  defect  in  mito-
chondrial biochemical function was found in the skeletal 
muscle of T2D subjects.
Despite  this  major  difference  in  study  interpretation 
and conclusion, all human microarray studies examining 
insulin resistance in skeletal muscle paint a remarkably 
similar  picture  -  one  of  no  striking  change  in  protein 
coding mRNA abundance. In the Patti et al. study [2], 
muscle  samples  from  a  small  group  of  subjects  of 
Mexican-American  ethnicity  were  studied  using  the 
Affymetrix HuGeneFL array platform, representing only 
15%  of  the  RNA  transcriptome,  and  no  significant 
differences were found. A gene-by-gene qPCR approach 
was also used, yielding evidence for reduced transcrip-
tional  regulators  of  OXPHOS  gene  expression  [2]. 
However, as oxidative metabolism proteins can be altered 
with physical inactivity [15], and a very large difference in 
demographics existed between the groups [2], then the 
observation  made  probably  does  not  reflect  diabetes. 
Another problem with the study by Patti et al. [2] was 
that  patients  were  taken  off  their  medication  only 
48  hours  prior  to  obtaining  the  muscle  biopsy.  In  the 
present  study  we  ensured  patients  with  T2D  ceased 
taking their hypoglycemic medication for 1 week prior to 
clinical measurements and muscle biopsy. Interestingly, 
short-term and long-term measures of glucose control - 
fasting glucose and HbA1c - remained highly correlated 
(R2  =  0.71)  in  our  study,  suggesting  that  after  being 
treated for a number of years, drug therapy was no longer 
providing a substantial influence on hyperglycemia [83]. 
This  discussion  highlights  the  possibility  that  protein 
signaling  changes  previously  ascribed  to  the  insulin 
resistance disease process [84] may in fact be a refractory 
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represent an artifact of study design.
Mootha  et  al.  [1]  studied  a  group  of  older  diabetes 
subjects  (approximately  66  years)  using  a  microarray 
platform  that  provides  greater  coverage  of  the  trans-
criptome (approximately 20,000 sequences). The authors 
applied  a  now  robust  statistical  approach  [54]  and 
presented evidence that there was a statistically signifi-
cant  down-regulation  of  a  group  of  genes  involved  in 
oxidative  metabolism  (OXPHOS)  in  skeletal  muscle  of 
T2D subjects, and claimed that this ‘gene set’ reflected 
reduced  PGC-1α  activity.  In  the  present,  much  larger 
analysis  we  did  not  identify  any  correlation  between 
glucose  or  insulin  levels  and  any  gene  set  including 
OXPHOS  or  PGC-1α.  To  examine  the  discrepancy 
between our data set and the Mootha et al. study [1], we 
ran  GSEA  on  a  subgroup  of  our  patients  that  closely 
approximated  the  demographics  of  their  study.  Hence, 
the only difference between the two studies should be the 
3-hour  hyperinsulinemia  exposure  prior  to  biopsy 
sampling in the Mootha et al. study. In our subjects, the 
OXPHOS gene set was ranked the least enriched gene set 
in the NGT subjects, supporting the idea that obtaining 
the  biopsy  samples  after  a  period  of  pharmacological 
hyperinsulinemia created an acute change in OXPHOS 
genes as T2D patients will respond differently to pharma-
cological levels of insulin infusion compared to control 
subjects  [3].  Thus,  although  substantial  loss  of 
mitochondrial function can cause metabolic dysfunction 
and muscle insulin resistance or diabetes [5], this is not 
synonymous with evidence that OXPHOS defects are a 
causal or primary defect in T2D and we cannot demon-
strate that such a defect exists in the skeletal muscle of 
diabetes  patients.  Further,  the  major  deter  minants  of 
skeletal  muscle  mitochondrial  status  -  physical  activity 
and physical fitness [85] - were not controlled for in any 
study and thus the OXPHOS-diabetes disease association 
should be considered unreliable.
Coordinated alteration in human skeletal muscle miRNA 
expression relates to insulin resistance in type 2 diabetes
We  provide  new  evidence  that  disrupted  miRNA 
expression  may  have  relevance  for  insulin  resistant 
skeletal  muscle.  Firstly,  one-third  of  miRNAs  robustly 
expressed  in  muscle  (62  out  of  171)  have  altered 
expression in diabetes patients and a subset of these is 
altered early in disease where patients remain untreated 
(Figure 2a). Secondly, we demonstrate that the highest 
ranked  wCCS  genes  belonged  to  relevant  biochemical 
processes,  namely  post-translational  modification  and 
metabolic pathways. Further, the genes ranked as being 
targeted most strongly by the collective net changes in 
miRNA  expression  target  approximately  six  significant 
canonical signaling pathways, five of which are described 
as related to insulin resistance or muscle metabolism [65-
75]. This level of statistical evidence is robust, especially 
when  one  considers  the  fourth  quartile  ranked  genes 
demonstrated no such associations.
Several  miRNAs  are  highly  regulated  in  vivo  and  in 
vitro during muscle development and these regulate the 
muscle differential expression process [55]. Most studied 
are miR-133, miR-206 and miR-1, which are all induced 
during differentiation of myoblasts into myotubes [28]. 
We were able to demonstrate using a separate detection 
system  that  altered  myomir  expression  varies  with 
disease severity and that gene-chip expression of a sub-
group  of  miRNAs  (10  out  of  11)  was  regulated  in  a 
manner  diametrically  opposite  that  observed  during 
muscle differentiation. Over-expression of miR-1 [55] or 
miR-206  [86]  in  mouse  myoblasts  accelerates  differen-
tiation  into  myotubes  whereas  over-expression  of 
miR-133 promotes proliferation [55]. In vivo the expres-
sion of these miRNAs can vary as miR-1 and miR-133a 
decrease 50% in response to muscle hypertrophy in mice 
following 7 days of loading [87]. As discussed below, and 
implicit in the successful identification of diabetes disease 
processes using the wCCS ranking approach and in vivo 
miRNA profiling, it is the combinatorial nature of miRNA 
action in vivo that seems to be most relevant. To this end 
we  have  been  able  to  call  the  protein  expression 
differences correctly (seven from seven) between controls 
and TD2 subjects using the wCCS ranking approach, and 
in doing so expand the evidence base for the involvement 
of  developmental  genes  in  muscle  insulin  resistance. 
These observations indicate that we have made progress 
in  addressing  a  major  challenge  in  the  miRNA  field, 
namely that of interpretation of biological consequences 
of in vivo multiple miRNA modulation [23].
Using the myomir family as an example, we attempted 
to establish why we observed changes in mature miRNA 
abundance. Current understanding of miRNA biogenesis 
and processing is primarily based on in vitro and genetic 
studies  in  lower  organisms  [88].  Mature  miRNAs  are 
derived from a longer primary transcript - approximately 
1 to 3 kb transcribed by RNA polymerase II [89] - that 
are then processed in the nucleus by Drosha to form an 
approximately  70-  to  80-nucleotide  precursor  miRNA 
[90]. This pre-miRNA is exported to the cytoplasm via 
Exportin 5 [91] where Dicer cleaves the pre-miRNA to 
leave  a  20-  to  22-nucleotide  mature  miRNA  that  is 
incorporated into a waiting RISC complex, where it can 
bind  complementary  target  mRNAs  and  suppress 
translation of multiple mRNAs. Many miRNAs are trans-
cribed as a ‘cluster’ from a single genomic region and it 
has been stated that for the myomirs, each should be co-
transcribed  and  co-expressed.  However,  evidence  of 
distinct  binding  proteins  that  modulate  processing  of 
pri-miRNA to mature miRNA [92] has emerged and we 
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miR-133a are not co-regulated in vivo in human skeletal 
muscle.  This  suggests  that  either  processing  of  the 
pri-miR-133a or stability of mature miR-133a is altered in 
T2D.  Regulation  of  miRNA  production,  post-trans-
criptionally,  is  proving  to  be  potentially  important  for 
determining  stem  cell  differentiation  [93,94]  while  the 
protein or signaling factors that inhibit miR-133a produc-
tion in T2D remain to be determined, this process clearly 
has the potential to alter muscle differentiation [28].
Human skeletal muscle insulin resistance and 
developmental genes
Given  the  chronic  nature  of  skeletal  muscle  insulin 
resistance  in  diabetes  and  the  role  of  satellite  cells  in 
maintaining long-term physiological function [95], it is 
surprising that so little is known about muscle stem cell 
status in T2D. So we were particularly interested in the 
idea  that  satellite  cell  function  may  be  altered  in  TD2 
[73].  Our  analysis  indicated  that  modulated  miRNAs 
collectively target developmental processes (P < 1.3 × 10-6) 
and thus we speculate that at least part of the disease 
process  occurs  within  the  skeletal  muscle  stem  cells 
(satellite  cells).  Disrupted  muscle  repair  would  be 
consistent  with  the  involvement  of  BDNF  expression 
inhibiting  myogenesis  [96]  and  we  demonstrated  that 
BDNF is elevated in proliferating satellite cells from diabetes 
patients (Figure 3c). Interestingly, BDNF mRNA expression 
is not altered by endurance training [18] and additional RT-
qPCR on this material (n = 24, data not shown) found it 
barely detectable in adult muscle tissue. Indeed, BDNF was 
only reliably detectable in activated muscle satellite cells. 
Studies on muscle damage in chemically induced diabetes 
models show impaired recovery [73], while this interesting 
link between diabetes, BDNF and muscle recovery remains 
to be studied in humans.
In  support  of  our  focus  on  developmental  genes, 
pathway  analysis  of  recent  genome-wide  association 
studies,  which  so  far  have  yielded  few  T2D  candidate 
genes,  provided  an  integrated  interpretation  of  the 
highest  ranked  risk  genes  for  T2D  [97].  This  analysis 
found  that  lipid  metabolism  and  developmental  genes 
were significantly over-represented in the upper ranked 
genes of the T2D genome-wide association studies, an 
observation  based  on  thousands  of  samples,  and  one 
strongly  consistent  with  the  present  independent 
analysis.  Combined,  we  believe  this  presents  strong 
evidence  that  developmental  genes  may  play  a  role  in 
setting or regulating the long-term responses of skeletal 
muscle to diabetes.
Conclusions
In  the  present  analysis,  we  provide  robust  evidence 
that  combining  multiple  single-gene  predictions 
produced  a  set  of  targets  that  could  be  validated  at 
several levels. Indeed, we have so far found the method 
to be 100% accurate. However, there are a number of 
additional  theoretical  considerations  that  need  to  be 
mentioned,  as  the  wCCS  method  currently  does  not 
include potentially important information. Firstly, we 
did  not  integrate  the  target  site  multiplicative  effect 
[33]  due  to  a  lack  of  information  on  the  synergy 
between the proximity of hetero  geneous miRNA target 
sites  and  protein  trans  lational  block.  Thus,  as  lower 
ranked protein targets are considered, the precision of 
the method may decline. Nor did we integrate absolute 
miRNA abundance data. Thus, we did not distinguish 
between  changes  in  high  abun  dance  and  low 
abundance  miRNAs.  The  main  reason  for  this 
omission  is  that  we  can  not  accurately  compare 
miRNA abundance across probes on a microarray, as 
each probe produces linear detection of single miRNA 
abundance  and  the  signal  is  not  designed  to  be 
compared across detection probes. Nevertheless, given 
the  enor  mous  range  of  probe  intensities,  it  is  likely 
that some changes do represent much larger absolute 
alterations in miRNA concentration than others. Thus, 
it may be possible to further refine the interpretation 
of coordi  nated in vivo changes in miRNA expression if 
we  adjust  the  wCCS  score  by  miRNA  absolute 
concentration. One needs to do this with some caution 
as the precise ‘potency’ of a given miRNA, as well as 
subcellular compart  mentalization, ensures that such a 
calculation is unlikely to be a simple linear one.
The  new  ranking  strategy  detects  relevant  biology 
without bias relating to protein isolation or chemistry 
and thus can aid pathway mining where clinical biopsy 
size  prevents  global  proteomics.  The  present  analysis 
indicates that collective miRNA changes in vivo should 
be  taken  into  account.  Technically,  it  would  be 
challenging to mimic this in cells as the simultaneous 
knock-down of 33 miRNA combined with over-expres-
sion  of  29  up-regulated  miRNAs,  all  at  the  correct 
dosage,  is  intractable  and  would  be  of  questionable 
physio  logical  relevance  in  a  cell  culture  system.  In 
conclusion, we provide the first global RNA profile of 
human  skeletal  muscle  insulin  resistance  and  demon-
strate  a  remarkably  invariant  mRNA  landscape.  We 
present  a  new  method  for  interpretation  of  multiple 
miRNA  changes  in  vivo,  analysis  that  extends  the 
evidence  that  developmental  genes  play  a  role  in 
metabolic  disease  [97,98].  miRNAs  can  be  robustly 
detected in minute amounts of RNA, collected by pain-
free micro-needle sampling, such that we believe they 
represent  plausible  biomarkers  of  muscle  status,  and 
may be useful for monitoring pharmacodynamics and 
early-stage  efficacy  during  larger-scale  diabetes 
intervention trials.
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